|
1
|
Wang D, Wong HK, Feng YB and Zhang ZJ:
18beta-glycyrrhetinic acid induces apoptosis in pituitary adenoma
cells via ROS/MAPKs-mediated pathway. J Neurooncol. 116:221–230.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu JK, Patel SK, Gillespie DL, Whang K
and Couldwell WT: R-flurbiprofen, a novel nonsteroidal
anti-inflammatory drug, decreases cell proliferation and induces
apoptosis in pituitary adenoma cells in vitro. J Neurooncol.
106:561–569. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feng J, Hong L, Wu Y, Li C, Wan H, Li G,
Sun Y, Yu S, Chittiboina P, Montgomery B, et al: Identification of
a subtype-specific ENC1 gene related to invasiveness in human
pituitary null cell adenoma and oncocytomas. J Neurooncol.
119:307–315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brychtova V, Vojtesek B and Hrstka R:
Anterior gradient 2: A novel player in tumor cell biology. Cancer
Lett. 304:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salmans ML, Zhao F and Andersen B: The
estrogen-regulated anterior gradient 2 (AGR2) protein in breast
cancer: A potential drug target and biomarker. Breast Cancer Res.
15:2042013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao H, Xu X, Chen B, Wang F, Zhang W, Geng
H and Wang Y: Anterior gradient 2: A new target to treat colorectal
cancer. Med Hypotheses. 80:706–708. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
DiMaio MA, Kwok S, Montgomery KD, Lowe AW
and Pai RK: Immunohistochemical panel for distinguishing esophageal
adenocarcinoma from squamous cell carcinoma: A combination of p63,
cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows
optimal subtyping. Human Pathol. 43:1799–1807. 2012. View Article : Google Scholar
|
|
8
|
Pizzi M, Fassan M, Balistreri M,
Galligioni A, Rea F and Rugge M: Anterior gradient 2 overexpression
in lung adenocarcinoma. Appl Immunohistochem Mol Morphol. 20:31–36.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen R, Pan S, Duan X, Nelson BH, Sahota
RA, de Rham S, Kozarek RA, McIntosh M and Brentnall TA: Elevated
level of anterior gradient-2 in pancreatic juice from patients with
pre-malignant pancreatic neoplasia. Mol Cancer. 9:1492010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Forootan SS, Liu D, Barraclough
R, Foster CS, Rudland PS and Ke Y: Increased expression of anterior
gradient-2 is significantly associated with poor survival of
prostate cancer patients. Prostate Cancer Prostatic Dis.
10:293–300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kani K, Malihi PD, Jiang Y, Wang H, Wang
Y, Ruderman DL, Agus DB, Mallick P and Gross ME: Anterior gradient
2 (AGR2): Blood-based biomarker elevated in metastatic prostate
cancer associated with the neuroendocrine phenotype. Prostate.
73:306–315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Li J, Tohti M, Hu Y, Wang S, Li W,
Lu Z and Ma C: The expression profile of Dopamine D2 receptor, MGMT
and VEGF in different histological subtypes of pituitary adenomas:
A study of 197 cases and indications for the medical therapy. J Exp
Clin Cancer Res. 33:562014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Di Ieva A, Rotondo F, Syro LV, Cusimano MD
and Kovacs K: Aggressive pituitary adenomas - diagnosis and
emerging treatments. Nat Rev Endocrinol. 10:423–435. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Z, Hao Y and Lowe AW: The
adenocarcinoma-associated antigen, AGR2, promotes tumor growth,
cell migration and cellular transformation. Cancer Res. 68:492–497.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fritzsche FR, Dahl E, Dankof A, Burkhardt
M, Pahl S, Petersen I, Dietel M and Kristiansen G: Expression of
AGR2 in non small cell lung cancer. Histol Histopathol. 22:703–708.
2007.PubMed/NCBI
|
|
16
|
Fritzsche FR, Dahl E, Pahl S, Burkhardt M,
Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, et
al: Prognostic relevance of AGR2 expression in breast cancer. Clin
Cancer Res. 12:1728–1734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang JS, Gong A, Cheville JC, Smith DI
and Young CY: AGR2, an androgen-inducible secretory protein
overexpressed in prostate cancer. Genes Chromosomes Cancer.
43:249–259. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu D, Rudland PS, Sibson DR,
Platt-Higgins A and Barraclough R: Human homologue of cement gland
protein, a novel metastasis inducer associated with breast
carcinomas. Cancer Res. 65:3796–3805. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vivekanandan P, Micchelli ST and Torbenson
M: Anterior gradient-2 is overexpressed by fibrolamellar
carcinomas. Hum Pathol. 40:293–299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee S, Bang S, Song K and Lee I:
Differential expression in normal-adenoma-carcinoma sequence
suggests complex molecular carcinogenesis in colon. Oncol Rep.
16:747–754. 2006.PubMed/NCBI
|
|
21
|
Adam PJ, Boyd R, Tyson KL, Fletcher GC,
Stamps A, Hudson L, Poyser HR, Redpath N, Griffiths M, Steers G, et
al: Comprehensive proteomic analysis of breast cancer cell
membranes reveals unique proteins with potential roles in clinical
cancer. J Biol Chem. 278:6482–6489. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao F, Edwards R, Dizon D, Afrasiabi K,
Mastroianni JR, Geyfman M, Ouellette AJ, Andersen B and Lipkin SM:
Disruption of Paneth and goblet cell homeostasis and increased
endoplasmic reticulum stress in Agr2-/- mice. Dev Biol.
338:270–279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Riener MO, Thiesler T, Hellerbrand C,
Amann T, Cathomas G, Fritzsche FR, Dahl E, Bahra M, Weichert W,
Terracciano L and Kristiansen G: Loss of anterior gradient-2
expression is an independent prognostic factor in colorectal
carcinomas. Eur J Cancer. 50:1722–1730. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Turner HE, Nagy Z, Esiri MM, Harris AL and
Wass JA: Role of matrix metalloproteinase 9 in pituitary tumor
behavior. J Clin Endocrinol Metab. 85:2931–2935. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu Z, Lee Vance M, Schlesinger D and
Sheehan JP: Hypopituitarism after stereotactic radiosurgery for
pituitary adenomas. Neurosurgery. 72:630–637, 636-637. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sattler MG, Vroomen PC, Sluiter WJ, Schers
HJ, van den Berg G, Langendijk JA, Wolffenbuttel BH, van den Bergh
AC and van Beek AP: Incidence, causative mechanisms and anatomic
localization of stroke in pituitary adenoma patients treated with
postoperative radiation therapy versus surgery alone. Int J Radiat
Oncol Biol Phys. 87:53–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
